BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 36811740)

  • 1. Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Novel Recombination Human Nerve Growth Factor in Healthy Chinese Subjects.
    Shen Q; Zhang M; Jin Y; Di X; Liu R; Wang Z
    CNS Drugs; 2023 Mar; 37(3):231-242. PubMed ID: 36811740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and pharmacokinetics of escalating doses of human recombinant nerve growth factor eye drops in a double-masked, randomized clinical trial.
    Ferrari MP; Mantelli F; Sacchetti M; Antonangeli MI; Cattani F; D'Anniballe G; Sinigaglia F; Ruffini PA; Lambiase A
    BioDrugs; 2014 Jun; 28(3):275-83. PubMed ID: 24327173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
    Fan Y; Zhang X; Zhang Q; Zheng L; Zhou R; Sun C; Wang X; Song K; He Z; Wang H; Zhang Q; Hu W
    Clin Pharmacokinet; 2024 Mar; 63(3):293-302. PubMed ID: 38198010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects.
    Guérard N; Morand O; Dingemanse J
    Orphanet J Rare Dis; 2017 Jan; 12(1):9. PubMed ID: 28088251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, and pharmacokinetics of ibrexafungerp in healthy Chinese subjects: a randomized, double-blind, placebo-controlled phase 1 trial.
    Liu X; Zhang R; Li R; Wu Q; Pan C; Yu X; Liu Y; Wang B; Yu S
    Antimicrob Agents Chemother; 2023 Dec; 67(12):e0107523. PubMed ID: 37971243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
    Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study.
    Sun L; Ding L; Wang Y; Zhou W; Yan Z; Sun W; Zhang H; Ou N; Chen X
    Drugs R D; 2012 Mar; 12(1):17-28. PubMed ID: 22339483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers.
    Li X; Li B; Wang M; Fang M; Lou J; Liu J; Chen H; Ding Y
    BioDrugs; 2024 Mar; 38(2):313-321. PubMed ID: 38148466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, Safety Profile, and Tolerability of Tetramethylpyrazine Nitrone Tablets After Single and Multiple Ascending Doses in Healthy Chinese Volunteers.
    Zhu G; Wang L; Zhong S; Han S; Peng H; Tong M; He X
    Eur J Drug Metab Pharmacokinet; 2024 Mar; 49(2):207-217. PubMed ID: 38381348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects.
    Liu X; Xue L; Zhang H; Xu Q; Zhang S; Ma S; Ding X; Liu L; Dong J; Qian L; Xia W; Jiang K; Huang C; Miao L
    Clin Drug Investig; 2020 Jun; 40(6):555-566. PubMed ID: 32277364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.
    Guo B; Wu X; Zhang Y; Shi Y; Yu J; Cao G; Zhang J
    Clin Drug Investig; 2012 Jul; 32(7):475-86. PubMed ID: 22650326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers.
    Shi S; Liu Y; Li Z; Wu J; Zhou X; Zeng F
    Arzneimittelforschung; 2012 Feb; 62(2):75-82. PubMed ID: 22344551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, Safety and Tolerability of Tylerdipine Hydrochloride, a Novel Dihydropyridine Dual L/T-type Calcium Channel Blocker, after Single and Multiple Oral Doses in Healthy Chinese Subjects.
    Zhou S; Wang Y; Wang L; Xie L; Chen J; Liu Y; Zhang H; Zhao Y; Ou N; Shao F
    Clin Drug Investig; 2019 Jan; 39(1):85-96. PubMed ID: 30368658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, pharmacokinetics, and pharmacodynamics of TG103, a novel long-acting GLP-1/Fc fusion protein after a single ascending dose in Chinese healthy subjects.
    Jin J; Cui G; Mi N; Wu W; Zhang X; Xiao C; Wang J; Qiu X; Han M; Li Z; Wang L; Lu T; Niu H; Wu Z; Li J
    Eur J Pharm Sci; 2023 Jun; 185():106448. PubMed ID: 37062422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 1 first-in-human study of the safety, tolerability, and pharmacokinetics of the ROBO2 fusion protein PF-06730512 in healthy participants.
    Lim CN; Kantaridis C; Huyghe I; Gorman D; Berasi S; Sonnenberg GE
    Pharmacol Res Perspect; 2021 Aug; 9(4):e00813. PubMed ID: 34369667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability and pharmacokinetics of trimebutine 3-thiocarbamoylbenzenesulfonate (GIC-1001) in a randomized phase I integrated design study: single and multiple ascending doses and effect of food in healthy volunteers.
    Paquette JM; Rufiange M; Iovu Niculita M; Massicotte J; Lefebvre M; Colin P; Telmat A; Ranger M
    Clin Ther; 2014 Nov; 36(11):1650-64. PubMed ID: 25224876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Expression Inhibitor GST-HG131 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial.
    Li X; Liu Y; Yao H; Wang M; Gao L; Lou J; Mao J; Wu W; Zhou Y; Tang Y; Yan W; Hu Y; Ding C; Chen S; Niu J; Ding Y
    Antimicrob Agents Chemother; 2022 May; 66(5):e0009422. PubMed ID: 35404074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-Compartmental Pharmacokinetics and Safety of Single-Dose Eldecalcitol (ED-71) in Healthy Chinese Adult Males.
    Zhao Q; Liu H; Jiang J; Wu Y; Zhong W; Li L; Miya K; Abe M; Hu P
    Clin Drug Investig; 2018 Oct; 38(10):901-908. PubMed ID: 30117129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, Tolerability, and Pharmacokinetics of the Monoamine Oxidase B Inhibitor, HEC122505, and its Major Metabolite After Single- and Multiple- Ascending Dose, and Food Effect Study in Healthy Chinese Subjects.
    Jin C; Yi C; Chen K; Liang H
    Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):331-341. PubMed ID: 38446388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study.
    Neelakantan S; Oemar B; Johnson K; Rath N; Salganik M; Berman G; Pelletier K; Cox L; Page K; Messing D; Tarabar S
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):307-316. PubMed ID: 33352008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.